527 related articles for article (PubMed ID: 32735525)
1. Spontaneous Adverse Drug Reaction Monitoring in a Tertiary Care Centre.
Kaur K; Kanwal P; Goyal P; Singh P; Yakhmi S; Jain S; Kaushal S
Curr Drug Saf; 2020; 15(3):215-221. PubMed ID: 32735525
[TBL] [Abstract][Full Text] [Related]
2. Adverse drug reactions at adverse drug reaction monitoring center in Raipur: Analysis of spontaneous reports during 1 year.
Singh P; Agrawal M; Hishikar R; Joshi U; Maheshwari B; Halwai A
Indian J Pharmacol; 2017; 49(6):432-437. PubMed ID: 29674797
[TBL] [Abstract][Full Text] [Related]
3. Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil.
Lobo MG; Pinheiro SM; Castro JG; Momenté VG; Pranchevicius MC
BMC Pharmacol Toxicol; 2013 Jan; 14():5. PubMed ID: 23298396
[TBL] [Abstract][Full Text] [Related]
4. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
[TBL] [Abstract][Full Text] [Related]
5. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
[TBL] [Abstract][Full Text] [Related]
6. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
Tandon VR; Mahajan V; Khajuria V; Gillani Z
Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
[TBL] [Abstract][Full Text] [Related]
7. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
Awodele O; Aliu R; Ali I; Oni Y; Adeyeye CM
Pharmacol Res Perspect; 2018 Oct; 6(5):e00427. PubMed ID: 30324768
[TBL] [Abstract][Full Text] [Related]
8. Inter-rater agreement between WHO- Uppsala Monitoring Centre system and Naranjo algorithm for causality assessment of adverse drug reactions.
More SA; Atal S; Mishra PS
J Pharmacol Toxicol Methods; 2024; 127():107514. PubMed ID: 38768933
[TBL] [Abstract][Full Text] [Related]
9. Pediatric pharmacovigilance in an institute of national importance: Journey has just begun.
Sharma PK; Misra AK; Gupta N; Khera D; Gupta A; Khera P
Indian J Pharmacol; 2017; 49(5):390-395. PubMed ID: 29515280
[TBL] [Abstract][Full Text] [Related]
10. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital.
Jose J; Rao PG
Pharmacol Res; 2006 Sep; 54(3):226-33. PubMed ID: 16781163
[TBL] [Abstract][Full Text] [Related]
11. Adverse drug reactions reported to a provincial public health sector pharmacovigilance programme in South Africa.
Jones J; Swart A; Tommy E; Cohen K; Stewart A; Voget J; Blockman M
S Afr Med J; 2020 Nov; 110(12):1226-1230. PubMed ID: 33403970
[TBL] [Abstract][Full Text] [Related]
12. Global patterns of adverse drug reactions over a decade: analyses of spontaneous reports to VigiBase™.
Aagaard L; Strandell J; Melskens L; Petersen PS; Holme Hansen E
Drug Saf; 2012 Dec; 35(12):1171-82. PubMed ID: 23072620
[TBL] [Abstract][Full Text] [Related]
13. Adverse Drug Reactions Spontaneously Reported at a Tertiary Care Hospital and Preventable Measures Implemented.
Abu Esba LC; Al Mardawi G; AlJasser MI; Aljohani B; Abu Alburak A
J Clin Pharm Ther; 2021 Apr; 46(2):460-469. PubMed ID: 33285001
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of reporting of adverse drug reactions to oncology drugs: An experience from a national center of clinical excellence.
Sharma PK; Misra AK; Gupta A; Singh S; Dhamija P; Pareek P
Indian J Pharmacol; 2018; 50(5):273-278. PubMed ID: 30636831
[TBL] [Abstract][Full Text] [Related]
15. Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India.
Prakash J; Sachdeva R; Shrivastava TP; Jayachandran CV; Sahu A
Indian J Pharmacol; 2021; 53(2):143-152. PubMed ID: 34100398
[TBL] [Abstract][Full Text] [Related]
16. Pharmacovigilance in children in Camagüey Province, Cuba.
Bárzaga Arencibia Z; López Leyva A; Mejías Peña Y; González Reyes AR; Fernández Manzano E; Choonara I
Eur J Clin Pharmacol; 2012 Jul; 68(7):1079-84. PubMed ID: 22315149
[TBL] [Abstract][Full Text] [Related]
17. Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009.
Aldea A; García Sánchez-Colomer M; Fernández Quintana E; García Sáiz M
Eur J Clin Pharmacol; 2012 Sep; 68(9):1329-38. PubMed ID: 22415248
[TBL] [Abstract][Full Text] [Related]
18. Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012.
Obebi Cliff-Eribo K; Sammons H; Star K; Ralph Edwards I; Osakwe A; Choonara I
Paediatr Int Child Health; 2016 Nov; 36(4):300-304. PubMed ID: 26384567
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Reporting Adverse Drug Reactions in Paediatric Patients in a University Hospital in the Netherlands.
Dittrich ATM; Draaisma JMT; van Puijenbroek EP; Loo DMWMT
Paediatr Drugs; 2020 Aug; 22(4):425-432. PubMed ID: 32557243
[TBL] [Abstract][Full Text] [Related]
20. Quantification of Adverse Drug Reactions Related to Drug Switches in The Netherlands.
Glerum PJ; Maliepaard M; de Valk V; Scholl JHG; van Hunsel FPAM; van Puijenbroek EP; Burger DM; Neef K
Clin Transl Sci; 2020 May; 13(3):599-607. PubMed ID: 32052597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
